PDCD1 and undifferentiated pleomorphic sarcoma: Data from clinical trials of anti-PD-1/PD-L1 immune checkpoint inhibitors (CPIs) have shown that a subset of UPS and DDLPS patients benefit from treatment with this class of drugs37,38.